One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8 + T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.
Blocking inhibitory immune receptors on activated tumor-reactive T cells has introduced a paradigm shift in cancer treatment. Targeting CTLA-4 and, in particular, the PD-1/PD-L1 axis has been extremely rewarding, resulting in the reinvigoration of an anti-tumor immune response, clinical objective responses, and improvement of outcome, especially in overall survival landmarks in a substantial number of cancer types. To exemplify this, in metastatic melanoma, around 50% of patients are still alive at 3 years following immune checkpoint blockade compared with 12% with dacarbazine, with more than 20% of patients in complete remission (Robert et al., 2011; Wolchok et al., 2017) . In addition, other immune inhibitory receptors on T cells are being targeted as well, including LAG-3, TIM-3, TIGIT, and BTLA. Preclinical models already showed synergism between blocking one of these ''new'' checkpoint in combination with anti-PD-1 /PD-L1 or anti-CTLA4 antibodies, and the first clinical data for some of these combinations look quite promising.
In this issue of Cell, another potential inhibitory molecule has been added to this growing list of receptors. NKG2A is a cell surface molecule, which is typically expressed by NK cells, but expression can be induced on T cells as well, especially on CD8 + T cells. NKG2A belongs to a family of lectins, which forms a heterodimer with CD94, also known as KLRD1, another NK cell expressed C-type lectin. The NKG2A/CD94 complex binds to the non-classical MHC I molecule, HLA-E in humans and Qa-1 b in mice and transduces inhibitory signals, which suppress NK and CD8+ T cells' activity (Braud et al., 1998) . HLA-E has broad tissue expression and has been demonstrated to have immunosuppressive function through binding to NKG2A (Kochan et al, 2013) . Importantly, HLA-E can also be (over)expressed on cancer cells, and this expression appears correlated with poor outcome (Levy et al., 2008) .
Two articles published in the current issue of Cell demonstrate that blocking NKG2A can improve the outcome of immunotherapies. The van Hall group demonstrates in 4 different mouse solid tumor models that peptide vaccination combined with antibody blockade of NKG2A on CD8 + T cells improves response rate and survival of these animals over peptide vaccination alone (van Montfoort et al., 2018, this issue of Cell). In addition, they show that Qa-1 b expression by tumor cells, but not by stromal or immune cells, is required for this additive effect. André et al. also show beneficial impact of NKG2A inhibition, but in combination with anti-PD-1/PD-L1 blockade in murine lymphoma tumor models and in human in vitro experiments , this issue of Cell). In addition, the preliminary results of a clinical trial in head and neck squamous cell carcinoma patients of combination of monalizumab, a NKG2A specific inhibitory humanized antibody, and cetuximab, an anti-EGFR antibody, led to a 30% objective response rate (ORR ie, proportion of patients with tumor size reduction of a predefined amount and for a minimum time period), even in immunotherapy refractory patients. The mechanism of action of this combination is most likely mediated by NKG2A expressing NK cells (ADCC) and not by NKG2A expressing CD8 + T cells.
Although these results are very promising and provide hope for future improve-ment of immunotherapies for cancer patients, many open questions remain.
First, little is known about the regulation of expression of both the receptor NKG2A/CD94 complex and the ligand. HLA-E/Qa-1 b is widely expressed and follows tissue distribution of classical HLA class I molecules. Like classical MHC molecules, HLA-E can be upregulated in an IFN-g dependent fashion, but it remains to be determined whether other cytokines may also play a role. Currently, the prerequisites for HLA-E expression by cancer cells is not fully understood and may be very much dependent on the tumor microenvironment and/or upregulation of signal peptidases involved in processing of the leader sequence peptides binding to HLA-E (Braud et al., 1998) . Second, we do not yet know why some subsets of CD8 + T cells express NKG2A, while the large proportion of CD4 + T cells are NKG2A negative. Utilizing a 36 parameter cyTOF platform, van Montfoort et al. (2018) show that NKG2A-expressing CD8 + T cells form a very distinct population of early activated tumor resident T cells within head and neck squamous cell carcinoma tumor-infiltrating lymphocytes. Bulk RNA-seq analysis of tumor-infiltrating lymphocytes coming from triple-negative breast cancer also show upregulated expression of NKG2A within the CD103 + T cells, but little is known about whether the NKG2A-expressing CD8 + T cells here comprises a specific subset of T cells (Savas et al. 2018) . In single-cell RNA-seq analyses of non-small cell lung cancer tumor-infiltrating lymphocytes or hepatocellular carcinoma-derived tumor-infiltrating lymphocytes, KLRC1 + population was not apparent. Data are emerging suggesting that CD103 + tumor-infiltrating lymphocytes accumulate inhibitory receptors, including PD-1, CTLA-4, TIM-3, LAG-3, etc., implying the development of an antigen-driven dysfunctional T cell state within the tumor micro-environment. Whether NKG2A expression is part of this development is currently not known. Co-expression of NKG2A and other immune checkpoint is, based on these two Cell studies, highly variable and very much depending on the model system used.
How should blockade of this novel immune checkpoint be optimally utilized? The current articles provide a couple of possibilities. First, although tumorinfiltrating NK cells express low levels of PD-1, blockade of PD-1 on NK cells has, so far, not yet resulted in important clinical effects. Most if not all anti-cancer responses unleashed by anti-PD-1 come from tumor-reactive T cells. NKG2A however, is constitutively expressed by NK cells, both peripheral blood and tumor infiltrating NK cells. André et al. (2018) demonstrate that antibody-dependent NK cell mediated cytotoxic activity can be enhanced by NKG2A blockade in vitro. The objective response rate observed in the clinical phase 2 trial combining anti-NKG2A with anti-EGFR in head and neck squamous cell carcinoma patients is at least suggestive of an enhanced antibody dependent cell-mediated cytotoxicity effect, although a comparative prospective trial will be , which bind to CD16, also known as FcgRIII, expressed by NK cells. Binding of HLA-E molecules expressed by tumor cells to the NKG2A/CD94 complex expressed by NK cells delivers a negative signal to NK cells, which are not able to perform ADCC. Upon addition of an anti-NKG2A antibody, blocking of NKG2A/CD94 binding to HLA-E leads to the activation of NK cells and secretion of granzymes, perforins, and cytokines like IFN-g. This will lead to enhanced ADCC and killing of the tumor cells. (B) Tumor cells and tumor-infiltrating CD8 T cells (TIL). Upon vaccination (peptide or RNA vaccines), the number of NKG2A + CD8 + TIL increases, whereas the tumor cells express Qa-1 b (murine homologue of HLA-E) (2nd panel). Binding of Qa-1 b to NKG2A leads to inactive T cell state. Combining anti-NKG2A and vaccination leads to enhanced activation state of the CD8 + TIL and improved tumor cell killing and survival. required to prove this. Should such comparative trial confirm lack of increased toxicity, combination of NKG2A blockade with tumor-targeting antibodies, unleashing NK cell anti-tumor reactivity, may become practice changing in the future ( Figure 1A) .
The second approach by van Montfoort et al. (2018) illustrates, in tumor mouse models, synergism between a therapeutic cancer vaccine and NKG2A inhibition ( Figure 1B) . As cancer vaccine development is undergoing a renaissance with emphasis on targeting tumor neoantigens, combinations with immune checkpoint blockade is obvious. Currently, trials are ongoing combining neoantigen RNA or synthetic long peptide vaccines with anti-PD-1/PD-L1 antibodies with so far promising results. Similarly, HPV synthetic long peptide vaccine combined with anti-PD-1 antibodies appears more efficacious than anti-PD-1 antibodies alone (Massarelli, et al., 2018) . Based on the preclinical data shown in these studies, demonstrating up-regulation of Qa-1 b in tumors upon vaccination and high levels of NKG2A expression in CD8 + tumor infiltrating lymphocytes, the combination of tumor vaccines with anti-NKG2A alone or in combination with another checkpoint inhibitor should be considered. In addition, recent work in the HIV field has identified strategies to induce broad virus-specific CD8 + T cell responses restricted by HLA-E in vaccinated rhesus macaques (Hansen et al. 2016) . This novel information could be exploited to induce T cell responses to HLA-E bound peptides derived from tumor antigens. Combination of these HLA-E targeting vaccines with an anti-NKG2A antibodies may further improve our current immunotherapies.
